{rfName}

Indexed in

License and use

Altmetrics

Analysis of institutional authors

Hernandez, A RodriguezAuthor

Share

October 22, 2024
Publications
>
Article
No

Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers

Publicated to:Annals Of Oncology. 35 (9): 792-804 - 2024-09-01 35(9), DOI: 10.1016/j.annonc.2024.06.009

Authors: Arecco, L; Bruzzone, M; Bas, R; Kim, H J; Di Meglio, A; Bernstein-Molho, R; Pogoda, K; Carrasco, E; Punie, K; Bajpai, J; Agostinetto, E; Lopetegui-Lia, N; Partridge, A H; Phillips, K A; Toss, A; Rousset-Jablonski, C; Curigliano, G; Renaud, T; Ferrari, A; Paluch-Shimon, S; Fruscio, R; Cui, W; Wong, S M; Vernieri, C; Couch, F J; Dieci, M V; Matikas, A; Rozenblit, M; Mendez, D Aguilar-y; De Marchis, L; Puglisi, F; Fabi, A; Graff, S L; Witzel, I; Hernandez, A Rodriguez; Fontana, A; Pesce, R; Duchnowska, R; Pais, H L; Sini, V; Sokolovic, E; de Azambuja, E; Ceppi, M; Blondeauxt, E; Lambertini, M

Affiliations

ASL Roma 1, Ctr Oncol Santo Spirito Nuovo Regina Margherita, Med Oncol, Rome, Italy - Author
August Pi i Sunyer Biomed Res Inst IDIBAPS, Translat Genom & Targeted Therapies Solid Tumors, Barcelona, Spain - Author
Azienda Osped Univ Modena, Dept Oncol & Haematol, Modena, Italy - Author
Azienda Osped Univ Pisana, Osped Santa Chiara, UO Oncol Med Univ 2, Pisa, Italy - Author
Bergonie Inst, Canc Genet Unit, Bordeaux, France - Author
Brown Univ, Lifespan Canc Inst, Legorreta Canc Ctr, Providence, RI USA - Author
Claude Bernard Lyon 1 Univ, Unite INSERM, U1290, RESHAPE, Lyon, France - Author
Cleveland Clin, Dept Hematol & Med Oncol, Taussig Canc Inst, Cleveland, OH USA - Author
Clin Ctr Univ Sarajevo, Oncol Clin, Sarajevo, Bosnia & Herceg - Author
Ctr Riferimento Oncol Aviano CRO IRCCS, Dept Med Oncol, Aviano, Italy - Author
Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA - Author
Fdn IRCCS Ist Nazl Tumori, Med Oncol Dept, Breast Unit, Milan, Italy - Author
Fdn IRCCS Policlin San Matteo, Surg Dept, Gen Surg Senol 3, Pavia, Italy - Author
Fdn IRCCS Policlinico San Matteo, Hereditary Breast & Ovarian Canc HBOC Unit, Pavia, Italy - Author
Fdn Policlin Univ Agostino Gemelli, IRCCS, Precis Med Unit Senol, Sci Directorate, Rome, Italy - Author
Gustave Roussy, Canc Survivorship Program Mol Predicitors & New Ta, INSERM, Unit 981, Villejuif, France - Author
Hebrew Univ Jerusalem, Hadassah Univ Hosp, Sharett Inst Oncol, Fac Med,Breast Oncol Unit, Jerusalem, Israel - Author
Homi Bhabha Natl Inst HBNI, Tata Mem Ctr, Mumbai, India - Author
Hosp Civils Lyon, Hop Femme Mere Enfant, Bron, France - Author
Hosp Clin Barcelona, Canc Inst & Blood Dis, Barcelona, Spain - Author
Hosp Italiano Buenos Aires, Reprod Med, Buenos Aires, Argentina - Author
Hosp Santa Maria, Ctr Hosp Univ Lisboa Norte, Dept Med Oncol, Lisbon, Portugal - Author
IRCCS Osped Policlin San Martino, Med Oncol Dept, UOC Clin Oncol Med, Genoa, Italy - Author
IRCCS Osped Policlin San Martino, UO Epidemiol Clin, Genoa, Italy - Author
IRCCS, European Inst Oncol, Milan, Italy - Author
Ist Oncol Veneto IOV IRCCS, Oncol 2, Padua, Italy - Author
Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden - Author
Karolinska Univ Hosp, Breast Ctr, Stockholm, Sweden - Author
Leon Berard Canc Ctr, Dept Surg, Lyon, France - Author
Maria Sklodowska Curie Natl Res Inst Oncol, Breast Canc & Reconstruct Surg Dept, PL-02781 Warsaw, Poland - Author
Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA - Author
McGill Univ, Jewish Gen Hosp, Med Sch, Dept Surg & Oncol, Montreal, PQ, Canada - Author
McGill Univ, Stroll Canc Prevent Ctr, Med Sch, Montreal, PQ, Canada - Author
Natl Res Inst, Mil Inst Med, Dept Oncol, Warsaw, Poland - Author
Netherlands Canc Inst NKI, Dept Mol Pathol, Amsterdam, Netherlands - Author
Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Australia - Author
Tecnol Monterrey, Hosp Zambrano Helliond TecSalud, Breast Canc Ctr, Monterrey, Mexico - Author
Tel Aviv Univ, Danek Gertner Inst Human Genet, Chaim Sheba Med Ctr, Susanne Levy Gertner Oncogenet Unit, Tel Hashomer, Israel - Author
Umberto Policlin Roma, Dept Hematol Oncol & Dermatol, Oncol Unit, Rome, Italy - Author
Univ Autonoma Barcelona, Univ Hosp Vall dHebron, Med Oncol Dept, Hereditary Canc Genet Grp,Vall dHebron Inst Oncol, Barcelona 08035, Spain - Author
Univ Genoa, Sch Med, Dept Internal Med & Med Specialties DiMI, Genoa, Italy - Author
Univ Hosp Leuven, Leuven Canc Inst, Dept Gen Med Oncol, Leuven, Belgium - Author
Univ Hosp Leuven, Leuven Canc Inst, Multidisciplinary Breast Ctr, Leuven, Belgium - Author
Univ libre Bruxelles ULB, Hop Univ Bruxelles HUB, Inst Jules Bordet, Acad Trials Promoting Team, Brussels, Belgium - Author
Univ Med Ctr Hamburg, Dept Gynaecol, Hamburg, Germany - Author
Univ Melbourne, Ctr Epidemiol & Biostat, Sch Populat & Global Hlth, Melbourne, Australia - Author
Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Australia - Author
Univ Milan, Dept Oncol & Hematooncol, Milan, Italy - Author
Univ Milan, Oncol & Hematol Oncol Dept, Milan, Italy - Author
Univ Milano Bicocca, Dept Med & Surg, UO Gynecol, IRCCS San Gerardo Tintori, Monza, Italy - Author
Univ Modena & Reggio Emilia, Dept Med & Surg Sci, Modena, Italy - Author
Univ Padua, Dipartimento Sci Chirurg Oncol & Gastroenterol, Padua, Italy - Author
Univ Paris Cite, Inst Curie, Dept Med Oncol, Paris, France - Author
Univ Pavia, Pavia, Italy - Author
Univ Roma La Sapienza, Dept Radiol Oncol & Pathol Sci, Div Med Oncol, Rome, Italy - Author
Univ Udine, Dept Med, Udine, Italy - Author
Univ Ulsan, Asan Med Ctr, Dept Surg, Div Breast Surg,Coll Med, Seoul, South Korea - Author
Univ Zurich, Dept Gynecol, Zurich, Switzerland - Author
Yale Univ, Dept Med Oncol, New Haven, CT USA - Author
See more

Abstract

Background: Hormone receptor expression is a known positive prognostic and predictive factor in breast cancer; however, limited evidence exists on its prognostic impact on prognosis of young patients harboring a pathogenic variant (PV) in the BRCA1 and/or BRCA2 genes. Patients and methods: This international, multicenter, retrospective cohort study included young patients (aged < 40 years) diagnosed with invasive breast cancer and harboring germline PVs in BRCA genes. We investigated the impact of hormone receptor status on clinical behavior and outcomes of breast cancer. Outcomes of interest [disease-free survival (DFS), breast cancer-specific fi c survival (BCSS), and overall survival (OS)] were fi rst investigated according to hormone receptor expression (positive versus negative), and then according to breast cancer subtype [luminal A-like versus luminal B-like versus triple-negative versus human epidermal growth factor receptor 2 (HER2)-positive breast cancer]. Results: From 78 centers worldwide, 4709 BRCA carriers were included, of whom 2143 (45.5%) had hormone receptor- positive and 2566 (54.5%) hormone receptor-negative breast cancer. Median follow-up was 7.9 years. The rate of distant recurrences was higher in patients with hormone receptor-positive disease (13.1% versus 9.6%, P < 0.001), while the rate of second primary breast cancer was lower (9.1% versus 14.7%, P < 0.001) compared to patients with hormone receptor-negative disease. The 8-year DFS was 65.8% and 63.4% in patients with hormone receptor-positive and negative disease, respectively. The hazard ratio of hormone receptor- positive versus negative disease changed over time for DFS, BCSS, and OS (P P < 0.05 for interaction of hormone receptor status and survival time). Patients with luminal A-like breast cancer had the worst long-term prognosis in terms of DFS compared to all the other subgroups (8-year DFS: 60.8% in luminal A-like versus 63.5% in triple- negative versus 65.5% in HER2-positive and 69.7% in luminal B-like subtype). Conclusions: In young BRCA carriers, differences in recurrence pattern and second primary breast cancer among hormone receptor-positive versus negative disease warrant consideration in counseling patients on treatment, follow-up, and risk-reducing surgery.

Keywords

AdultAnthracycline derivativeAntineoplastic agentAntineoplastic hormone agonists and antagonistsAromatase inhibitorArticleBiomarkers, tumorBrcaBrca1 proteinBrca1 protein, humanBrca2 proteinBrca2 protein, humanBreast cancer molecular subtypeBreast cancer specific survivalBreast neoplasmsBreast tumorBreast-conserving surgeryCancer centerCancer chemotherapyClinical featureClinical outcomeClinical trialCohort analysisControlled studyDisease free survivalDisease-free survivalEarly breast cancerEpidermal growth factor receptor 2Erbb2 protein, humanEstrogen receptorFemaleFollow upGenetic variabilityGeneticsGerm-line mutationGermline mutationGonadorelin agonistHazard ratioHeterozygoteHormone receptorHormone receptor negative breast cancerHormone receptor positive breast cancerHormone receptor statusHumanHuman epidermal growth factor receptor 2 negative breast cancerHuman epidermal growth factor receptor 2 positive breast cancerHumansInvasive breast cancerLuminal a breast cancerLuminal b breast cancerMajor clinical studyMastectomyMetabolismMonotherapyMortalityMulticenter studyMutationOverall survivalPathologyPatient selectionPrimary tumorProgesterone receptorPrognosisProtein expressionRateReceptor, erbb-2Receptors, estrogenReceptors, progesteroneRecurrence scoreRetrospective studiesRetrospective studyRisksSurvival timeTamoxifenTaxane derivativeTriple negative breast cancerTumor markerTumor subtypeTumor subtypesTumor suppressor geneYoung adultYoung patients

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Annals Of Oncology due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2024 there are still no calculated indicators, but in 2023, it was in position 4/326, thus managing to position itself as a Q1 (Primer Cuartil), in the category Oncology. Notably, the journal is positioned above the 90th percentile.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2025-07-22:

  • WoS: 5
  • Scopus: 2

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-22:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 26.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 54 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 27.95.
  • The number of mentions on the social network X (formerly Twitter): 33 (Altmetric).
  • The number of mentions in news outlets: 1 (Altmetric).

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Argentina; Australia; Belgium; Canada; France; Germany; India; Israel; Italy; Jerusalem; Mexico; Netherlands; Poland; Portugal; Republic of Korea; Sweden; Switzerland; United States of America.